SCHEMBL1998769

SCHEMBL1998769

N#Cc1ccc2ncc(-c3nccc(NCc4ccc(F)cc4)n3)n2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 3/20 0.53
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
CLK4 Q9HAZ1 4/20 0.45
DYRK1A Q13627 2/20 0.45
CYP1A2 P05177 3/20 0.44
CYP2C19 P33261 3/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
LMNA P02545 1/20 0.44
NTRK1 P04629 2/20 0.43
NTRK3 Q16288 2/20 0.43
NTRK2 Q16620 2/20 0.43
VNN1 O95497 1/20 0.43
FLT3 P36888 2/20 0.42
JAK2 O60674 1/20 0.42
ABL1 P00519 1/20 0.42
INSR P06213 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2000446 0.90 KIT (0.60) KITALDH1A1KDM4ECLK4DYRK1A
SCHEMBL1992563 0.89 NTRK1 (0.58) KITALDH1A1CLK4DYRK1ACYP1A2
SCHEMBL1997645 0.81 EIF2AK4 (0.45) KITFLT3JAK2EIF2AK4IRAK1
SCHEMBL1993309 0.80 KIT (0.47) KITALDH1A1CLK4DYRK1ACYP1A2
SCHEMBL1996723 0.80 JAK2 (0.47) KITALDH1A1CLK4CYP1A2CYP2C19
SCHEMBL1993894 0.77 IRAK4 (0.46) KITFLT3JAK2EIF2AK4EGLN2
SCHEMBL1992847 0.76 EIF2AK4 (0.45) KITCYP3A4FLT3JAK2EIF2AK4
SCHEMBL1998010 0.74 IRAK4 (0.49) KITFLT3JAK2EIF2AK4IRAK1
SCHEMBL2038246 0.74 KIT (0.51) KITALDH1A1KDM4ECLK4DYRK1A
SCHEMBL12615878 0.74 KIT (0.64) KITALDH1A1KDM4ECLK4DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US claimed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP claimed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO claimed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP claimed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP disclosed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 KIT 161/4885ALDH1A1 1435/4885KDM4E 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.